BBIO - Company ID 0001743881
The table below shows BridgeBio Pharma, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $570.12M | $681.10M | $375.94M | $376.69M | $393.77M | $356.08M |
| Short-term investments | - | - | $0.00 | $51.58M | $393.74M | $251.01M |
| Receivables | $139.44M | $4.72M | - | - | - | - |
| Inventory | $26.75M | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $797.75M |
| $720.69M |
| $477.59M |
| $548.85M |
| $888.86M |
| $642.82M |
| Property, plant & equipment | $5.37M | $7.01M | $11.82M | $14.57M | $30.07M | $20.32M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $936.02M | $919.34M | $546.38M | $623.04M | $1.01B | $703.59M |
| Accounts payable | $36.23M | $9.62M | $10.65M | $11.56M | $11.88M | $8.95M |
| Total current liabilities | $287.97M | $154.40M | $143.84M | $121.43M | $135.07M | $95.65M |
| Long-term debt | $2.01B | $437.34M | $446.44M | $430.99M | $430.75M | $92.42M |
| Total liabilities | $3.01B | $2.38B | $1.89B | $1.87B | $1.88B | $595.70M |
| Retained earnings | -$3.82B | -$3.10B | -$2.56B | -$1.92B | -$1.44B | -$888.75M |
| Total equity | -$2.09B | -$1.47B | -$1.35B | -$1.25B | -$870.41M | $57.91M |